East Tallinn Central Hospital
Welcome,         Profile    Billing    Logout  
 33 Trials 
57 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Metges, Jean-Philippe
RePERSO, NCT04874207: Evaluation of Treatment PERSOnalization Based on Its Therapeutic Monitoring in Patients with Metastatic Colorectal Cancer Treated with REgorafenib

Active, not recruiting
4
110
Europe
Regorafenib
Rennes University Hospital
Colorectal Cancer Metastatic
06/25
12/25
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
PHARBEVACOL, NCT06642844: Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Not yet recruiting
3
244
NA
Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group
University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy
Unresectable Metastatic Colorectal Cancer
10/28
10/29
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial

Recruiting
2
252
Europe
Unsupervised APA program, Supervised APA program
Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreas Cancer, Quality of Life
02/22
08/24
CAIRE, NCT04705818: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
OPTIPRIME, NCT03584711: FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation

Active, not recruiting
2
118
Europe, RoW
FOLFOX + panitumumab
Federation Francophone de Cancerologie Digestive, Amgen
Metastatic Colorectal Cancer
12/24
12/24
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
POCHI, NCT04262687: Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune Infiltrate

Recruiting
2
55
Europe
Capecitabine, Oxaliplatin, Bevacizumab, Pembrolizumab
Federation Francophone de Cancerologie Digestive
Colorectal Cancer Metastatic, High Immune Infiltrate, Microsatellite Stable
09/24
09/24
GRECO-2, NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Terminated
2
177
Europe, Canada, US
Drug GC4711, Placebo
Galera Therapeutics, Inc.
SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
11/23
11/23
NCT05503797: A Study to Assess the Efficacy and Safety of FORE8394 in Participants with Cancer Harboring BRAF Alterations

Recruiting
2
250
Europe, Canada, US, RoW
Plixorafenib, FORE8394, PLX8394, Cobicistat, TYBOST(R)
Fore Biotherapeutics
Cancer Harboring BRAF Alterations
06/25
08/26
LOGICAN, NCT05476796: Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer

Recruiting
2
118
Europe
Trifluridine/Tipiracil, Lonsurf, Oxaliplatin, FOLFOX regimen, Nivolumab, OPDIVO
UNICANCER, Servier
Gastric Adenocarcinoma, Esophagus Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
01/26
01/27
REGOMUNE, NCT03475953: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors

Recruiting
1/2
747
Europe
Phase 1 : Regorafenib, Phase 1 : Avelumab, Phase 2 : Regorafenib, Phase 2 : Avelumab, Phase 2: low-dose Regorafenib
Institut Bergonié, Bayer, Merck KGaA, Darmstadt, Germany
Colorectal Cancer Not MSI-H or MMR-deficient, GIST, Oesophageal or Gastric Carcinoma, Biliary Tract Cancer, Hepatocellular Carcinoma, Soft-tissue Sarcoma, Thyroid Cancer, Gastro-enteropancreatic Neuroendocrine Tumor, Non-small Cell Lung Cancer, Solid Tumor, Adult, Urothelial Carcinoma, HPV-Related Carcinoma, Triple Negative Breast Cancer, Renal Carcinoma, Mesotheliomas Pleural
12/24
12/25
TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
159
Europe, US
TNG462
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
COPE, NCT04258137: Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study

Recruiting
N/A
332
Europe
Liquid biopsy
Institut Bergonié
Colorectal Cancer, Non Small Cell Lung Cancer
09/24
04/25
GRAMMY, NCT04842916: InteGRAtive Analysis of TuMor, Microenvironment, ImmunitY and Patient Expectation for Personalized Response Prediction in Gastric Cancer

Recruiting
N/A
250
Europe
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, ERA PERMED
Gastric Cancer
05/27
05/27
Nishina, Tomohiro
ALTAIR, NCT04457297: Initial Attack on Latent Metastasis Using TAS-102 for ct DNA Identified Colorectal Cancer Patients After Curative Resection

Recruiting
3
240
Japan, RoW
trifluridine and tipiracil, Placebo
National Cancer Center Hospital East, Alpha-A, Inc.
Colorectal Neoplasms, Trifluridine and Tipiracil, Circulating Tumor DNA
05/23
12/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Talli, Jaak
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
12000
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
Ojamaa, Kristiina
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
Kuusk, Gerli
CANFOUR, NCT03267316 / 2017-001111-36: A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors

Completed
1/2
167
Europe
CAN04, Cisplatin, Gemcitabine, Nab-paclitaxel, Carboplatin, Pemetrexed
Cantargia AB
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
03/24
03/24
GUIMBAUD, Rosine
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
PHARBEVACOL, NCT06642844: Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Not yet recruiting
3
244
NA
Avastin, 25 Mg/mL Intravenous Solution, Experimental group, Control group
University Hospital, Tours, CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, CHU de Clermont-Ferrand, CHU de Reims, CHU de Brest, AP-HP, Hôpital Pitié- Salpétrière, CHU de Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, AP-HP, Hôpital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, CHU de Nancy
Unresectable Metastatic Colorectal Cancer
10/28
10/29
OSCAR, NCT02885753: Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting
3
348
Europe
Oxaliplatin intravenous, Oxaliplatin IV, 5 FU bolus, 5 FU, Folinic acid, Folinic Acid IV, Oxaliplatin intra-arteriel, Oxaliplatin IA, Panitumumab, Pani, Bevacizumab, Beva, 5 FU continuous, Irinotecan, IRI
Federation Francophone de Cancerologie Digestive
Colorectal Neoplasms
09/25
09/27
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
APACaPOp, NCT03400072: Adapted Physical Activity in Patients With Resected Pancreatic Cancer ( PRODIGE-56 Study): a National Multicenter Randomized Controlled Phase II Trial

Recruiting
2
252
Europe
Unsupervised APA program, Supervised APA program
Centre Hospitalier Universitaire de Besancon, GERCOR - Multidisciplinary Oncology Cooperative Group
Pancreas Cancer, Quality of Life
02/22
08/24
MAZEPPA, NCT04348045: Personalized Maintenance Therapy for m-PDAC Using Olaparib or Selumetinib + Durvalumab, Based on BRCAness and KRAS Status.

Active, not recruiting
2
307
Europe
Arm A - Olaparib, AZD-2281, ARM B - durvalumab plus selumetinib, MEDI-4736 plus AZD-6244, ARM C FOLFIRI, folinic acid, fluorouracil, and irinotecan
GERCOR - Multidisciplinary Oncology Cooperative Group, AstraZeneca
Metastatic Pancreatic Adenocarcinoma
07/23
12/24
NEONIPIGA, NCT04006262: Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.

Checkmark Data from NEONIPIGA trial of nivolumab/ipilimumab neoadjuvant therapy in dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma
Aug 2022 - Aug 2022: Data from NEONIPIGA trial of nivolumab/ipilimumab neoadjuvant therapy in dMMR/MSI-H gastric or gastroesophageal junction adenocarcinoma
Recruiting
2
32
Europe
Nivolumab 10 MG/ML, Opdivo, Ipilimumab 200 MG in 40 ML Injection, Yervoy
GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb
Localized Oesogastric Adenocarcimona, MSI and or dMMR
06/24
06/24
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (non-colorectal/non-endometrial) with Tumor DMMR/MSI

Recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
ARION, NCT03777813 / 2018-000708-40: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer

Active, not recruiting
2
112
Europe
Durvalumab, IMRT 50 Gy + FOLFOX4 simplifIed (oxaliplatin, leucovorin, 5-FU)
UNICANCER
Esophagus Cancer, Unresectable Malignant Neoplasm
09/25
09/25
PREMICES, NCT06646445: Neoadjuvant Pembrolizumab with a Watch-and-wait Strategy for Patients with DMMR/MSI-H Localized Colon Cancer: GERCOR G-109 PRODIGE 84 Phase II Trial

Not yet recruiting
2
64
Europe
Pembrolizumab 200mg IV q3w day 1 of 21-day cycle, Keytruda, Watch-and-wait approach, Surgery, Adjuvant chemotherapy
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Colon Cancer
10/27
10/29
NIPISAFE, NCT04730544: Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC.

Recruiting
2
96
Europe
Nivolumab 480mg + Ipilimumab, Opdivo, Yervoy, Nivolumab 240 mg + Ipilimumab
GERCOR - Multidisciplinary Oncology Cooperative Group, Bristol-Myers Squibb
Colorectal Cancer Metastatic, MSI-H Colorectal Cancer
04/27
04/28
BETTER 2, NCT03351296: Two Chemotherapy Regimens Plus or Minus Bevacizumab

Active, not recruiting
2
140
Europe
LV5FU2, Streptozocin, Capecitabine, Temozolomide, Bevacizumab
Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France
Pancreatic Cancer
12/28
12/28
NEONEC, NCT04268121: Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas

Recruiting
2
78
Europe
Neoadjuvant treatment, cisplatin / cisplatinum, etoposide / vepesid, carbopatin / paraplatin, Adjuvant treatment
GERCOR - Multidisciplinary Oncology Cooperative Group, Fondation ARCAD
Neuroendocrine Carcinoma, Digestive Cancer
01/34
06/34
BACAP-2, NCT06128343: Anatomical-Clinical Base of Adenocarcinoma Pancreatic

Recruiting
N/A
1500
Europe
collection of biological samples
University Hospital, Toulouse
Adenocarcinoma, Carcinoma, Neoplasms
01/35
02/35
DECIDE, NCT03958240: Deciphering Mechanisms Underlying Cancer Immunogenicity

Recruiting
N/A
900
Europe
Blood samples, tumor biopsy specimens and ascites samples will be collected.
Institut Claudius Regaud
Head and Neck Cancer, Ovarian Cancer, Cervical Cancer, Cervical Intraepithelial Neoplasia 3, Glioblastoma Multiforme of Brain Stem, Non Small Cell Lung Cancer, Anal Cancer
09/29
09/29
NCT05103969: Cohort of Tumors With POLE/D1 Mutation

Recruiting
N/A
100
Europe
Federation Francophone de Cancerologie Digestive
Tumors, POLE Exonuclease Domain Mutation, POLD1 Gene Mutation
10/25
10/25
Ilmoja, Mari-Liis
TREOCAPA, NCT04459117 / 2019-004297-26: Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen

Active, not recruiting
2/3
824
Europe
Acetaminophen, NACL 0.9%
Institut National de la Santé Et de la Recherche Médicale, France, UPCET, PARTNERS for International clinical Research, European Fundation for the Care of the Newborn Infants, Connect for Children
Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity
07/24
07/24
Andresson, Pille
TREOCAPA, NCT04459117 / 2019-004297-26: Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen

Active, not recruiting
2/3
824
Europe
Acetaminophen, NACL 0.9%
Institut National de la Santé Et de la Recherche Médicale, France, UPCET, PARTNERS for International clinical Research, European Fundation for the Care of the Newborn Infants, Connect for Children
Patency of the Ductus Arteriosus, Acetaminophen, Extreme Prematurity
07/24
07/24
Sym, Sun-Jin
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
Kang, Beodeul
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

Recruiting
3
200
Europe, US, RoW
Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice
TransThera Sciences (Nanjing), Inc.
Cholangiocarcinoma
05/26
08/26
SHR-A1904-I-104, NCT05277168: A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Recruiting
1/2
83
US, RoW
SHR-A1904
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
03/26
05/26
HOMECARE, NCT05636384: SupporTive Care At Home Research for Patients With Advanced Cancer (STAHR-cancer)

Recruiting
N/A
396
RoW
Home-based care
Seoul National University Hospital, Chung-Ang University Hosptial, Chung-Ang University College of Medicine, DongGuk University, Kyung Hee University Hospital, Bundang CHA Hospital, Seoul National University Bundang Hospital
Malignant Neoplasm, Home Care Services, Quality of LIfe, Unplanned Hospitalization
12/26
12/26
Esko, Vivian
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
Ress, Krista
NCT05368285 / 2021-006413-11: A Phase 2 Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Active, not recruiting
2
208
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics
Chronic Spontaneous Urticaria
09/23
03/25
CDX0159-07, NCT05405660 / 2021-006447-95: A Study of CDX-0159 in Patients With Chronic Inducible Urticaria

Active, not recruiting
2
196
Europe, US, RoW
barzolvolimab, CDX-0159, Matching Placebo
Celldex Therapeutics, Celldex Therapeutics, Inc.
Chronic Inducible Urticaria
06/24
09/25
Yamaguchi, Toshifumi
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
12/24
07/25
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
Seire, Indrek
NORPPA-1, NCT06328361: Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer

Recruiting
N/A
200
Europe
Nonoperative surveillance, Watch and Wait, Organ preservation
Tampere University Hospital, Tampere University, Helsinki University Central Hospital, Turku University Hospital, Kuopio University Hospital, Oulu University Hospital, Jyväskylä Central Hospital, Seinajoki Central Hospital, Satakunta Central Hospital, North Karelia Central Hospital, Tartu University Hospital, East Tallinn Central Hospital, West Tallinn Central Hospital, North Estonia Medical Centre
Rectal Cancer, Rectal Adenocarcinoma
12/28
12/32
Mettis, Mihkel
NORPPA-1, NCT06328361: Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer

Recruiting
N/A
200
Europe
Nonoperative surveillance, Watch and Wait, Organ preservation
Tampere University Hospital, Tampere University, Helsinki University Central Hospital, Turku University Hospital, Kuopio University Hospital, Oulu University Hospital, Jyväskylä Central Hospital, Seinajoki Central Hospital, Satakunta Central Hospital, North Karelia Central Hospital, Tartu University Hospital, East Tallinn Central Hospital, West Tallinn Central Hospital, North Estonia Medical Centre
Rectal Cancer, Rectal Adenocarcinoma
12/28
12/32

Download Options